Prostate Cancer

Scott T. Tagawa, MD, discusses an emerging treatment modality for patients with progressive metastatic castration-resistant prostate cancer.

Higher survival rates were observed with radical prostatectomy and adjuvant radiotherapy compared with radiotherapy and androgen deprivation therapy in men with locally advanced prostate cancer.

A panel of experts has recommended hypofractionated radiation as an alternative to longer, conventional courses of radiation for men with earlystage prostate cancer who opt for external beam radiation therapy.

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the use of prostate-specific membrane antigen (PSMA)-targeted imaging in patients with metastatic castration-resistant prostate cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use granted support for approval of apalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease.

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the importance of exercise in the management of prostate cancer treatment-related adverse events.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the rationale for radiotherapy in the treatment of newly-diagnosed metastatic prostate cancer.

Mark Emberton, MD, FRCS, discusses updates in the diagnosis and treatment of patients with localized prostate cancer.

James Kearns, MD, discusses key issues to consider with surgery in patients with high-risk prostate cancer.

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, addresses issues in the diagnosis of localized prostate cancer.

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses radiotherapy in the treatment of patients with prostate cancer.

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the role of immunotherapy in prostate cancer.

Earle Burgess, MD, discusses the shifting paradigm of metastatic castration-sensitive prostate cancer.

James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses factors to consider when choosing treatment for a patient with prostate cancer.

Darolutamide significantly improved metastasis-free survival versus placebo in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.

Deborah A. Bradley, MD, discusses how recent clinical trials have impacted patients with nonmetastatic castration-resistant prostate cancer and what the future holds for them.

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, discusses the synergy between abiraterone acetate (Zytiga) and androgen deprivation therapy (ADT) in prostate cancer.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.

Preliminary data from the ongoing phase II TRITON2 trial demonstrated a 44% confirmed objective response rate by investigator assessment among evaluable men with BRCA1/2-mutated metastatic castration-resistant prostate cancer who were treated with the PARP inhibitor rucaparib.

When added to standard of care therapy, radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden.